SCHEMBL6746768

SCHEMBL6746768

N#CC(C#N)c1cccc(C(O)c2ccncc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 3/20 0.42
CYP11B1 P15538 2/20 0.42
CYP11B2 P19099 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP19A1 P11511 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.40
SLC6A2 P23975 2/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A3 Q01959 2/20 0.37
PGR P06401 1/20 0.36
TSHR P16473 1/20 0.36
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
BRD4 O60885 1/20 0.33
ESR1 P03372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4380408 0.80 CYP19A1 (0.42) CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1
SCHEMBL6748329 0.80 LSS (0.41) CYP19A1PGRTSHRCA1CA2
SCHEMBL17064649 0.79 CA1 (0.51) CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1
SCHEMBL28425960 0.75 SLC6A2 (0.42) CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1
SCHEMBL23882733 0.74 CYP11B1 (0.46) CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1
SCHEMBL18280131 0.74 CYP11B1 (0.46) CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1
SCHEMBL8736883 0.74 CYP19A1 (0.46) CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1
SCHEMBL14685882 0.74 CYP19A1 (0.46) CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1
SCHEMBL477399 0.73 SMN1; SMN2 (0.65) CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1
SCHEMBL7680971 0.73 CYP3A4 (0.67) CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087583-A1 Amino-thio-acrylonitriles as MEK inhibitors HOBBS FRANK WORDEN (US) 2004-05-06 US disclosed
US-6703420-B1 MITOGEN ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS; ANTIINFLAMMATORY, ANTICARCINOGENIC, OR ANTIPROLIFERATIVE AGENTS; RADIOSENSITIZERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-03-09 US disclosed
EP-1163215-A1 AMINO-THIO-ACRYLONITRILES AS MEK INHIBITORS Du Pont Pharmaceuticals Company (US) 2001-12-19 EP disclosed
WO-2000056706-A1 AMINO-THIO-ACRYLONITRILES AS MEK INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087583-A1 Amino-thio-acrylonitriles as MEK inhibitors MAPK1, MAP3K1, CDKN1A CYP17A1 3243/4885CYP11B1 825/4885CYP11B2 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.